湘股1月26日涨幅TOP5 长沙晚报掌上长沙1月26日讯 截至1月26日收盘：沪指跌0.09%，报4132.6052点；深证成指跌0.85%，报 14316.637点。 湖南黄金开盘价25.270，收盘报25.270元，当日涨10.01%，当日最高价为25.270元，最低价为25.270元，成 交量7.9635万手。 湖南白银开盘价17.430，收盘报18.080元，当日涨9.98%，当日最高价为18.080元，最低价为17.430元，成 交量399.6619万手。 唐人神开盘价4.300，收盘报4.510元，当日涨5.13%，当日最高价为4.510元，最低价为4.250元，成交量 104.7088万手。 *ST高斯开盘价12.750，收盘报12.730元，当日涨4.86%，当日最高价为12.750元，最低价为12.380元，成交 量14.1327万手。 汉森制药开盘价6.920，收盘报7.050元，当日涨2.17%，当日最高价为7.170元，最低价为6.840元，成交量 19.401万手。 MACD金叉信号形成，这些股涨势不错！ 梦洁股份（维权）开盘价4.930，收盘报4.580元，当日跌-7.10%，当日 ...

证券日报网讯1月23日，汉森制药（002412）在互动平台回答投资者提问时表示，百贝益肺胶囊的主要 功能为滋阴润肺，止咳化痰。用于治疗肺阴不足咳嗽；慢性支气管炎咳嗽。 ...

证券日报网讯 1月20日，汉森制药在互动平台回答投资者提问时表示，公司可在互动易平台回复非定期 报告时点的月末股东人数，截至2025年12月31日公司的股东人数，公司将在2025年年度报告中披露，后 续可关注公司在指定信息披露媒体及巨潮资讯网披露的相关公告。 （文章来源：证券日报） ...

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.11% on January 12, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index closed at 14366.91, up by 1.75% [1] Stock Performance - Wanbangde (002082) closed at 16.56, with a significant increase of 10.03% and a trading volume of 376,100 shares, amounting to 615 million yuan [1] - Zhenbaodao (603567) rose by 4.62% to close at 9.74, with a trading volume of 185,700 shares [1] - Taiji Group (600129) increased by 2.79% to 19.16, despite a decrease in trading volume of 146,600 shares [1] - Renhe Pharmaceutical (000650) and other companies also showed positive growth, with Renhe closing at 6.18, up by 2.15% [1] Capital Flow - The traditional medicine sector experienced a net outflow of 550 million yuan from institutional investors, while retail investors contributed a net inflow of 460 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde saw a net inflow of 95.22 million yuan from institutional investors, but a net outflow from retail investors of 67.16 million yuan [3] - Other companies like Jianxin Pharmaceutical (002412) and Jilin Aodong (000623) also experienced varying degrees of net inflows and outflows from different investor categories [3]

证券日报网讯1月8日，汉森制药（002412）在互动平台回答投资者提问时表示，公司始终高度重视股东 回报，相关决策严格遵循法律法规及公司章程规定。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a 2.71% increase in stock price on December 19, with a trading volume of 66.22 million yuan, indicating positive market sentiment [1] - On December 19, Hansen Pharmaceutical had a financing buy amount of 7.61 million yuan and a financing repayment of 10.93 million yuan, resulting in a net financing buy of -3.32 million yuan [1] - As of December 19, the total balance of margin trading for Hansen Pharmaceutical was 146 million yuan, which represents 4.25% of its circulating market value, indicating a relatively high level compared to the past year [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include: Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and others, with a total revenue of 741 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 6.75% [2] - The net profit attributable to the parent company for the same period was 82.53 million yuan, showing a year-on-year decrease of 36.88% [2] Group 3 - Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Hansen Pharmaceutical was 24,100, an increase of 0.85% from the previous period [3] - The eighth largest circulating shareholder is Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, holding 2.11 million shares as a new shareholder [3]

证券日报网讯12月19日，汉森制药（002412）在互动平台回答投资者提问时表示，公司的研发情况请参 考公司定期报告。 ...

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]

证券日报网讯12月15日，汉森制药（002412）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司含信用账户合并股东名册的股东总数为24145户。 ...